Zoetis-Neogen genomics business deal raises antitrust concerns in New Zealand
( July 9, 2026, 07:51 GMT | Official Statement) -- MLex Summary: Global animal health company Zoetis’ proposed acquisition of Neogen Corporation is raising antitrust concerns for New Zealand’s competition regulator. In a statement on Thursday, the New Zealand Commerce Commission, without confirming a date, said that it will soon publish a statement of issues outlining the regulator’s potential competition issues with the acquisition following its initial investigation. In a statement of preliminary issues published in May, the regulator said that in New Zealand, Zoetis and Neogen provide genetic testing services for livestock to farmers. Zoetis is seeking to acquire the global animal genomic-testing business of Neogen.Statement follows....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.